Mirae Asset Global Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$121K Sell
2,596
-395
-13% -$19K ﹤0.01% 1204
2026
Q1
$155K Sell
2,991
-5,099
-63% -$260K ﹤0.01% 1109
2025
Q4
$402K Buy
8,090
+618
+8% +$30K ﹤0.01% 1037
2025
Q3
$357K Buy
7,472
+5,309
+245% +$214K ﹤0.01% 1044
2025
Q2
$68.2K Buy
2,163
+295
+16% +$9.45K ﹤0.01% 1209
2025
Q1
$60.3K Buy
1,868
+28
+2% +$992 ﹤0.01% 1208
2024
Q4
$68.4K Sell
1,840
-153
-8% -$5.39K ﹤0.01% 1212
2024
Q3
$61.3K Buy
1,993
+352
+21% +$11K ﹤0.01% 1266
2024
Q2
$44.1K Sell
1,641
-21,638
-93% -$627K ﹤0.01% 1274
2024
Q1
$843K Sell
23,279
-530
-2% -$15.8K ﹤0.01% 1631
2023
Q4
$689K Buy
23,809
+872
+4% +$23.1K ﹤0.01% 1811
2023
Q3
$632K Buy
22,937
+51
+0.2% +$1.55K ﹤0.01% 1767
2023
Q2
$688K Sell
22,886
-101
-0.4% -$3.53K ﹤0.01% 1793
2023
Q1
$833K Buy
22,987
+652
+3% +$25.1K ﹤0.01% 1636
2022
Q4
$797K Buy
22,335
+33
+0.1% +$1.15K ﹤0.01% 1626
2022
Q3
$755K Buy
22,302
+6,263
+39% +$204K ﹤0.01% 1641
2022
Q2
$463K Buy
+16,039
New +$459K ﹤0.01% 1787

Other funds holding SUPN

Mirae Asset Global Investments's SUPN Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Supernus Pharmaceuticals (SUPN) stake by 13% in Q2 2026, selling an estimated $19K and leaving 2,596 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #1204.

Mirae Asset Global Investments first reported a position in SUPN in Q2 2022 and has held it in 17 quarters since. The position peaked at $843K in Q1 2024. 131 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Mirae Asset Global Investments held 2,596 shares of Supernus Pharmaceuticals worth $121K as of Q2 2026.
  • Mirae Asset Global Investments sold 395 Supernus Pharmaceuticals shares in Q2 2026, an estimated $19K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1204 holding.
  • Mirae Asset Global Investments first reported a position in Supernus Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • Mirae Asset Global Investments's Supernus Pharmaceuticals position peaked at $843K in Q1 2024.
  • 131 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.